Art. -Nr.: HY-N1437

Hydroxycitric acid

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

Hydroxycitric acid is an orally active, multi-target, multi-bioactive organic acid. activates Nrf2 and its downstream molecule GPX4, increases glutathione levels, and thereby inhibits ferroptosis. Hydroxycitric acid activates the Nrf2/Keap1 and ACLY/NF-κB signaling pathways, upregulates the activities of antioxidant enzymes such as superoxide dismutase, reduces MDA content, thereby alleviating oxidative stress and renal tubular epithelial cell apoptosis, and improves pulmonary vascular and right ventricular remodeling. Hydroxycitric acid activates both the AMPK and mTORC1/S6K pathways, triggers the unfolded protein response, arrests the cancer cell cycle, and induces DNA fragmentation.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.31%
CAS. Nr.: 6205-14-7
Formel: C₆H₈O₈
Molecular Weight:208.12

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Hydroxycitric acid Chemical Structure

CAS. Nr.: 6205-14-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen :

Alle NF-κB Isoform-spezifische Produkte anzeigen :

Alle mTOR Isoform-spezifische Produkte anzeigen :

Alle Ribosomal S6 Kinase (RSK) Isoform-spezifische Produkte anzeigen :

Alle AMPK Isoform-spezifische Produkte anzeigen :

In Vitro

Hydroxycitric acid (1-100 mM; 72 h) potently inhibits the proliferation of K562, MEG-01, CML-T1, KYO-1 and SKH-1 chronic myeloid leukemia (CML) cell lines, with IC₅₀ values ranging from 3.73 to 11.34 mM; in contrast, it exerts no effect on normal mouse embryonic fibroblasts even at concentrations as high as 100 mM^[1].
Hydroxycitric acid (0.5-5 mM) induces DNA fragmentation in K562 chronic myeloid leukemia (CML) cells^[1].
Hydroxycitric acid (0.5-10 mM; 48-72 h) induces G₂/M cell cycle arrest in K562 chronic myeloid leukemia (CML) cells^[1].
Hydroxycitric acid (0.5-5 mM, 24-48 h) activates AMPK by increasing the phosphorylation level of T172 in K562, MEG-01, KYO-1 and SKH-1 chronic myeloid leukemia (CML) cells, without altering the total protein level of AMPK^[1].
Hydroxycitric acid (0.5-1 mM; 24-48 h) activates both the AMPK and mTORC1 pathways, and triggers the unfolded protein response in K562 chronic myeloid leukemia (CML) cells by upregulating the phosphorylation level of eIF2α and the expression level of ATF4^[1].
Hydroxycitric acid (5-10 mM) significantly inhibits hypoxia-induced proliferation of human pulmonary artery smooth muscle cells at concentrations of 5 mM and 10 mM^[3].
Hydroxycitric acid (matched to hypoxic/normoxic exposure conditions) inhibits the proliferation of human pulmonary artery smooth muscle cells under both normoxic and hypoxic conditions, with a stronger inhibitory effect on cells in a hypoxic environment^[3].
Hydroxycitric acid (24 h) significantly inhibits hypoxia-induced migration of human pulmonary artery smooth muscle cells^[3].
Hydroxycitric acid (overnight) significantly reduces hypoxia-induced reactive oxygen species production in human pulmonary artery smooth muscle cells^[3].
Hydroxycitric acid (combined with hypoxic exposure) significantly reduces the expression of hypoxia-inducible factor-1 (HIF-1) mRNA in hypoxia-induced human pulmonary artery smooth muscle cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis^[1]

Cell Line:

K562 CML cells
Concentration:

0.5, 5 and 10 mM
Incubation Time:

48 h; 72 h
Result:

Caused a significant accumulation of K562 cells in the G2/M phase of the cell cycle after 48 h treatment with 10 mM.
Caused significant accumulation of cells in the G2/M phase after 72 h treatment with 5 mM and 10 mM.

Western Blot Analysis^[1]

Cell Line:

CML cell lines K562, MEG-01, KYO-1, SKH-1
Concentration:

0.5 and 1 mM (K562); 0.5-5 mM (MEG-01, KYO-1, SKH-1)
Incubation Time:

24 and 48 h (K562); 24 h (MEG-01, KYO-1, SKH-1)
Result:

Significantly increased phosphorylation of AMPKα at T172 in all tested CML cell lines without altering total AMPKα protein levels.
Increased p-AMPKα levels by ~2-, ~6-, and ~4-fold in MEG-01 cells at 0.5 mM, 1 mM, and 5 mM doses, respectively.
Increased p-AMPKα levels by ~1.5-, ~1.2-, and ~1-fold in KYO-1 cells at 0.5 mM, 1 mM, and 5 mM doses, respectively.
Increased p-AMPKα levels by ~30-fold in SKH-1 cells at 5 mM dose.

Western Blot Analysis^[1]

Cell Line:

K562 CML cells
Concentration:

0.5 and 1 mM
Incubation Time:

24 and 48 h
Result:

Increased phosphorylation of AMPKα, ACC, p70 S6 kinase, S6 ribosomal protein, and eIF2α, and increased ATF4 protein levels.
Indicated concurrent activation of the AMPK and mTORC1 pathways, plus activation of the unfolded protein response.\nShowed AMPK and ACLY interacted in K562 cells via co-immunoprecipitation.
Reduced the total level of immunoprecipitated AMPK-ACLY complex, but the ratio of immunoprecipitated ACLY to AMPK remained unchanged compared to untreated controls, indicating no effect on the interaction between the two proteins.

Western Blot Analysis^[1]

Cell Line:

K562 CML cells
Concentration:

1 mM
Incubation Time:

24 and 48 h
Result:

Confirmed a fraction of AMPK co-eluted with ACLY, showing they are part of a common protein complex.
Had no major effect on the migration of this protein complex.

In Vivo

Hydroxycitric acid (3 mg/kg; p.o.; daily; 25 days) reduces the final tumor volume to 1/3 of the original level and significantly decreases tumor weight in a chronic myeloid leukemia xenograft mouse model^[1].
Hydroxycitric acid (250 mg/kg; i.p.; administered daily for 4 consecutive weeks) significantly reduces monocrotaline-induced pulmonary arterial hypertension in rats, decreases RVSP by 28.97% via anti-inflammatory and anti-fibrotic effects, and ameliorates right ventricular and pulmonary vascular remodeling^[3].
hydroxycitrate (250 mg/kg; i.p.; administered daily for 4 consecutive weeks) significantly alleviates hypoxia-induced pulmonary arterial hypertension in rats, reduces RVSP by 17.5% via anti-inflammatory and antioxidant effects, and improves right ventricular and pulmonary vascular remodeling^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

NOD.Cg-PrkdcscidIl2rgtm1WjI/SzJ (NSG) (male, 8-10 weeks old)^[1]
Dosage:

3 mg/kg
Administration:

p.o.; daily; 25 days
Result:

Reduced final average tumor volume.

Animal Model:

Sprague-Dawley (male, 8-10 weeks old, hypobaric hypoxia-induced model)^[3]
Dosage:

250 mg/kg/day
Administration:

i.p.; daily; 4 weeks
Result:

Reduced RVSP from 42.30 mmHg to 34.9 mmHg.
Decreased right ventricular index from 32.62% to 26.11%.
Reduced right ventricular fibrotic area from 8.94% to 5.80%.
Attenuated upregulated collagen-1 mRNA levels.
Reduced pulmonary arteriole medium film layer thickness from 33.57 μm to 22.29 μm.
Decreased vascular wall area ratio from 0.71% to 0.45%.
Reduced serum IL-1β levels from 66.50 pg/mL to 55.80 pg/mL.
Increased cardiac SOD concentration from 7.31 U/mg to levels significantly higher than hypoxia-only controls.
Reduced cardiac H₂O₂ concentration from 8.76 mM to levels significantly lower than hypoxia-only controls.

Animal Model:

Sprague-Dawley (male, 8-10 weeks old, monocrotaline-induced model)^[3]
Dosage:

250 mg/kg/day
Administration:

i.p.; daily; 4 weeks
Result:

Reduced right ventricular systolic pressure (RVSP) from 47.60 mmHg to 33.81 mmHg .
Decreased right ventricular index from 39.7% to 26.48%.
Decreased right ventricular weight/body weight ratio from 0.87 mg/g to 0.63 mg/g.
Reduced right ventricular fibrotic area from 15.40% to 8.82%.
Attenuated upregulated mRNA levels of α-SMA, collagen-1, and collagen-3.
Reduced pulmonary arteriole medium film layer thickness from 30.14 μm to 21.86 μm.
Decreased vascular wall area ratio from 0.65% to 0.51%.
Reduced serum levels of IL-6 from 121.20 pg/mL to 59.73 pg/mL, and TNF-α from 19.13 pg/mL to 11.82 pg/mL.
Suppressed elevated p-IκBα and p65 protein expressions in lung tissue.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 6205-14-7
Appearance Solid
Molecular Weight 208.12
Formel C₆H₈O₈
Color White to off-white
SMILES

OC(C(C(O)=O)O)(C(O)=O)CC(O)=O
Structure Classification
- Ketones, Aldehydes, Acids
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

Polymers

High-Expansion Natural Composite Films for Controlled Delivery of Hydroxycitric Acid in Obesity Therapy. [Abstract]

2025 Jun 18;17(12):1697. PMID: 40574227

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 1.92 mg/mL (9.23 mM; ultrasonic and warming and adjust pH to 7 with 1 M HCL and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.8049 mL

24.0246 mL

48.0492 mL

5 mM

0.9610 mL

4.8049 mL

9.6098 mL

10 mM

---

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (287 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Verrelli D, et al. Hydroxycitric Acid Inhibits Chronic Myelogenous Leukemia Growth through Activation of AMPK and mTOR Pathway. Nutrients. 2022;14(13):2669. Published 2022 Jun 27. [Content Brief]

[2]. Yang D, et al. Hydroxycitric acid inhibits ferroptosis and ameliorates benign prostatic hyperplasia by upregulating the Nrf2/GPX4 pathway. World J Urol. 2025;43(1):318. Published 2025 May 20. [Content Brief]

[3]. Wang S, et al. Hydroxycitric Acid Tripotassium Hydrate Attenuates Monocrotaline and Hypoxia-Induced Pulmonary Hypertension in Rats. Int Heart J. 2024;65(2):318-328. [Content Brief]

[4]. Yang B, et al. Hydroxycitric acid prevents hyperoxaluric-induced nephrolithiasis and oxidative stress via activation of the Nrf2/Keap1 signaling pathway. Cell Cycle. 2023;22(17):1884-1899. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.8049 mL	24.0246 mL	48.0492 mL	120.1230 mL
DMSO	5 mM	0.9610 mL	4.8049 mL	9.6098 mL	24.0246 mL

Keywords

Hydroxycitric acid

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Hydroxycitric acid

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

MAPK Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Ferroptosis Compound Library

Endoplasmic Reticulum Stress Compound Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Food Additive Library

Inactive Ingredient Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Plant-Sourced Natural Product Library

Anti-Pulmonary Fibrosis Compound Library

Cuproptosis Compound Library

Pain-Related Compound Library

Metabolic Enzyme Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Dietary Supplement Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Hydroxycitric acid

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen

Alle NF-κB Isoform-spezifische Produkte anzeigen

Alle mTOR Isoform-spezifische Produkte anzeigen

Alle Ribosomal S6 Kinase (RSK) Isoform-spezifische Produkte anzeigen

Alle AMPK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise